Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation

David Lowance, Hans H. Neumayer, Christophe M. Legendre, Jean Paul Squifflet, Josef Kovarik, Patrick J. Brennan, Douglas Norman, Rafael Mendez, Michael R. Keating, Gary L. Coggon, Adam Crisp, Ira C. Lee

Research output: Contribution to journalArticle

589 Citations (Scopus)

Abstract

Background: Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease. Methods: A total of 208 CMV-negative recipients of a kidney from a seropositive donor and 408 CMV- positive recipients were randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 days after transplantation, with the dose adjusted according to renal function. The primary end point was laboratory-confirmed CMV disease in the first six months after transplantation. Results: Treatment with valacyclovir reduced the incidence or delayed the onset of CMV disease in both the seronegative patients (P

Original languageEnglish (US)
Pages (from-to)1462-1470
Number of pages9
JournalNew England Journal of Medicine
Volume340
Issue number19
DOIs
StatePublished - May 13 1999

Fingerprint

valacyclovir
Cytomegalovirus
Kidney Transplantation
Transplantation
Kidney
Organ Transplantation
Placebos
Tissue Donors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lowance, D., Neumayer, H. H., Legendre, C. M., Squifflet, J. P., Kovarik, J., Brennan, P. J., ... Lee, I. C. (1999). Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. New England Journal of Medicine, 340(19), 1462-1470. https://doi.org/10.1056/NEJM199905133401903

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. / Lowance, David; Neumayer, Hans H.; Legendre, Christophe M.; Squifflet, Jean Paul; Kovarik, Josef; Brennan, Patrick J.; Norman, Douglas; Mendez, Rafael; Keating, Michael R.; Coggon, Gary L.; Crisp, Adam; Lee, Ira C.

In: New England Journal of Medicine, Vol. 340, No. 19, 13.05.1999, p. 1462-1470.

Research output: Contribution to journalArticle

Lowance, D, Neumayer, HH, Legendre, CM, Squifflet, JP, Kovarik, J, Brennan, PJ, Norman, D, Mendez, R, Keating, MR, Coggon, GL, Crisp, A & Lee, IC 1999, 'Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation', New England Journal of Medicine, vol. 340, no. 19, pp. 1462-1470. https://doi.org/10.1056/NEJM199905133401903
Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. New England Journal of Medicine. 1999 May 13;340(19):1462-1470. https://doi.org/10.1056/NEJM199905133401903
Lowance, David ; Neumayer, Hans H. ; Legendre, Christophe M. ; Squifflet, Jean Paul ; Kovarik, Josef ; Brennan, Patrick J. ; Norman, Douglas ; Mendez, Rafael ; Keating, Michael R. ; Coggon, Gary L. ; Crisp, Adam ; Lee, Ira C. / Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. In: New England Journal of Medicine. 1999 ; Vol. 340, No. 19. pp. 1462-1470.
@article{66bfc0d3bf114d329730853a218a3f63,
title = "Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation",
abstract = "Background: Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease. Methods: A total of 208 CMV-negative recipients of a kidney from a seropositive donor and 408 CMV- positive recipients were randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 days after transplantation, with the dose adjusted according to renal function. The primary end point was laboratory-confirmed CMV disease in the first six months after transplantation. Results: Treatment with valacyclovir reduced the incidence or delayed the onset of CMV disease in both the seronegative patients (P",
author = "David Lowance and Neumayer, {Hans H.} and Legendre, {Christophe M.} and Squifflet, {Jean Paul} and Josef Kovarik and Brennan, {Patrick J.} and Douglas Norman and Rafael Mendez and Keating, {Michael R.} and Coggon, {Gary L.} and Adam Crisp and Lee, {Ira C.}",
year = "1999",
month = "5",
day = "13",
doi = "10.1056/NEJM199905133401903",
language = "English (US)",
volume = "340",
pages = "1462--1470",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "19",

}

TY - JOUR

T1 - Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation

AU - Lowance, David

AU - Neumayer, Hans H.

AU - Legendre, Christophe M.

AU - Squifflet, Jean Paul

AU - Kovarik, Josef

AU - Brennan, Patrick J.

AU - Norman, Douglas

AU - Mendez, Rafael

AU - Keating, Michael R.

AU - Coggon, Gary L.

AU - Crisp, Adam

AU - Lee, Ira C.

PY - 1999/5/13

Y1 - 1999/5/13

N2 - Background: Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease. Methods: A total of 208 CMV-negative recipients of a kidney from a seropositive donor and 408 CMV- positive recipients were randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 days after transplantation, with the dose adjusted according to renal function. The primary end point was laboratory-confirmed CMV disease in the first six months after transplantation. Results: Treatment with valacyclovir reduced the incidence or delayed the onset of CMV disease in both the seronegative patients (P

AB - Background: Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease. Methods: A total of 208 CMV-negative recipients of a kidney from a seropositive donor and 408 CMV- positive recipients were randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 days after transplantation, with the dose adjusted according to renal function. The primary end point was laboratory-confirmed CMV disease in the first six months after transplantation. Results: Treatment with valacyclovir reduced the incidence or delayed the onset of CMV disease in both the seronegative patients (P

UR - http://www.scopus.com/inward/record.url?scp=0033551348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033551348&partnerID=8YFLogxK

U2 - 10.1056/NEJM199905133401903

DO - 10.1056/NEJM199905133401903

M3 - Article

C2 - 10320384

AN - SCOPUS:0033551348

VL - 340

SP - 1462

EP - 1470

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 19

ER -